Today, Xylem Inc. (XYL) gets “Neutral” status at Boenning Scattergood

Today, Xylem Inc. (XYL) gets “Neutral” status at Boenning Scattergood

Boenning Scattergood cut shares of Xylem Inc. (NYSE:XYL) from an outperform rating to a neutral rating in a research note released on Monday morning.

Several other brokerages have also issued reports on XYL. Royal Bank Of Canada lifted their price target on shares of Xylem from $47.00 to $51.00 and gave the company an outperform rating in a research note on Tuesday, August 16th. RBC Capital Markets set a $51.00 price target on shares of Xylem and gave the company a buy rating in a research note on Tuesday, August 16th. Canaccord Genuity reiterated a hold rating and issued a $50.00 price target (up from $45.00) on shares of Xylem in a research note on Tuesday, August 16th. Atlantic Securities upgraded shares of Xylem from a neutral rating to an overweight rating and set a $54.00 price target on the stock in a research note on Monday, August 22nd. Finally, Janney Montgomery Scott upgraded shares of Xylem from a neutral rating to a buy rating and lifted their price target for the company from $50.00 to $52.00 in a research note on Wednesday, November 2nd. Eight equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Xylem currently has an average rating of Buy and a consensus target price of $47.15.

Shares of Xylem (NYSE:XYL) opened at 51.64 on Monday. The firm’s 50-day moving average is $50.32 and its 200-day moving average is $48.42. Xylem has a 12-month low of $31.67 and a 12-month high of $54.99. The company has a market capitalization of $9.26 billion, a PE ratio of 28.66 and a beta of 1.18.

Xylem (NYSE:XYL) last announced its quarterly earnings results on Tuesday, November 1st. The company reported $0.54 earnings per share for the quarter, topping analysts’ consensus estimates of $0.53 by $0.01. Xylem had a net margin of 8.83% and a return on equity of 16.38%. The company had revenue of $897 million for the quarter, compared to analysts’ expectations of $913.53 million. During the same period last year, the firm posted $0.49 earnings per share. The business’s quarterly revenue was down .6% compared to the same quarter last year. On average, equities research analysts anticipate that Xylem will post $2.04 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 7th. Shareholders of record on Wednesday, November 9th will be issued a $0.1549 dividend. This represents a $0.62 dividend on an annualized basis and a yield of 1.17%. The ex-dividend date of this dividend is Monday, November 7th. Xylem’s dividend payout ratio is currently 34.44%.

In other Xylem news, SVP Claudia S. Toussaint sold 5,300 shares of the business’s stock in a transaction dated Friday, November 4th. The shares were sold at an average price of $47.27, for a total value of $250,531.00. Following the completion of the sale, the senior vice president now owns 44,033 shares of the company’s stock, valued at approximately $2,081,439.91. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Colin R. Sabol sold 27,473 shares of the business’s stock in a transaction dated Thursday, September 8th. The shares were sold at an average price of $50.91, for a total transaction of $1,398,650.43. Following the completion of the sale, the insider now directly owns 65,530 shares of the company’s stock, valued at approximately $3,336,132.30. The disclosure for this sale can be found here. 0.77% of the stock is currently owned by company insiders.

A number of hedge funds have recently bought and sold shares of the stock. ETRADE Capital Management LLC acquired a new stake in Xylem during the third quarter worth about $358,000. Scout Investments Inc. acquired a new stake in Xylem during the third quarter worth about $27,492,000. Price T Rowe Associates Inc. MD increased its stake in Xylem by 0.4% in the third quarter. Price T Rowe Associates Inc. MD now owns 9,831,231 shares of the company’s stock worth $515,648,000 after buying an additional 40,520 shares in the last quarter. Quantitative Systematic Strategies LLC acquired a new stake in Xylem during the third quarter worth about $548,000. Finally, Somerville Kurt F increased its stake in Xylem by 1.6% in the third quarter. Somerville Kurt F now owns 77,688 shares of the company’s stock worth $4,074,000 after buying an additional 1,200 shares in the last quarter. 86.38% of the stock is owned by hedge funds and other institutional investors.

Xylem Company Profile

Related posts

Leave a Comment